DIN 02438364 — SYNAGIS 100 MG
SYNAGIS is a solution of Palivizumab marketed by ASTRAZENECA CANADA INC. The full Palivizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02438364
- Brand name
- SYNAGIS
- Active ingredient
- Palivizumab
- Strength
- 100 MG
- Dosage form
- SOLUTION
- Route
- INTRAMUSCULAR
- Manufacturer
- ASTRAZENECA CANADA INC
- Health Canada status
- DORMANT
- Drug class
- Humanized monoclonal antibody (RSV F protein inhibitor, passive immunizing agent)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Palivizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02438372 | SYNAGIS | 50 MG | SOLUTION | ASTRAZENECA CANADA INC | DORMANT |